Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vaxcyte, Inc. (PCVX : NSDQ)

• Company Description    Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California. Number of Employees: 414

• Price / Volume Information    Yesterday's Closing Price: $33.27 Daily Weekly Monthly 20 Day Moving Average: 1,483,580 shares Shares Outstanding: 129.00 (millions) Market Capitalization: $4,291.97 (millions) Beta: 1.19 52 Week High: $121.06 52 Week Low: $27.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.68% -5.74% 12 Week 8.02% -5.35% Year To Date -59.36% -61.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 825 INDUSTRIAL ROAD STE. 300 - SAN CARLOS,CA 94070 USA ph: 650-837-0111 fax: - investors@vaxcyte.com https://vaxcyte.com

• General Corporate Information    Officers Grant E. Pickering - Chief Executive Officer and Director Andrew Guggenhime - President and Chief Financial Officer Elvia Cowan - Senior Vice President and Finance Carlos Paya - Director Annie Drapeau - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92243G108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/05/25 Share - Related Items Shares Outstanding: 129.00 Most Recent Split Date: (:1) Beta: 1.19 Market Capitalization: $4,291.97 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.16 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 3.26% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.34 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -22.35% vs. Previous Quarter: -1.96% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -17.12 12/31/24 - -17.35 ROA 06/30/25 - - 03/31/25 - -16.26 12/31/24 - -16.50 Current Ratio 06/30/25 - - 03/31/25 - 17.70 12/31/24 - 12.76 Quick Ratio 06/30/25 - - 03/31/25 - 17.70 12/31/24 - 12.75 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 24.81 12/31/24 - 26.52 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©